RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), PRIME (European Union)

Structure/Sequence

Molecular FormulaC19H19N3O3

InChIKeyFWCVZAQENIZVMY-UHFFFAOYSA-N

CAS Registry1446321-46-5

Clinical Trials associated with Voxelotor

NCT06023199

/ Active, not recruitingPhase 2IIT

Assessing Functional Capacity in Sickle Cell Patients Receiving Voxelotor

Voxelotor is a novel hemoglobin polymerization inhibitor which has been demonstrated to reduce hemolysis and improve hemoglobin levels. There have been numerous studies examining the clinical impact of voxelotor in sickle cell disease (SCD) patients, but there are few published reports on the effects of treatment on physical function in patients with SCD. The hypothesis to be tested is that anemic SCD patients will have improvements in performance after 6 months of voxelotor treatment.

Start Date23 Oct 2023

Sponsor / Collaborator

Inova Health Care Services

[+1]

NCT05228821

/ WithdrawnPhase 4

An Open Label, Single Arm, Multicenter Study to Evaluate the Effect of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Adolescents and Adults With Sickle Cell Disease

This is an open label, single arm multicenter trial to evaluate the effect of voxelotor treatment on cerebral blood flow (CBF) and neurocognitive function in adolescent and young adult participants (12-30 years of age) with sickle cell disease (SCD).

Start Date09 Aug 2023

Sponsor / Collaborator

Pfizer Inc.

NCT05981365

/ CompletedPhase 1

A Phase 1, Open-Label, Two-Part, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Voxelotor on the Pharmacokinetics of Selected CYP and Transporter Probe Substrates in Healthy Participants

This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are metabolized by cytochrome enzymes. The substrates used in this study are FDA approved medications). The study will help to determine the safety and tolerability of the study drugs taken together, as well as the pharmacokinetics (PK) on how your body processes and responds to the combination of the study drug and substrates. Although these drugs are FDA approved, their use in this study is experimental.

Start Date17 Apr 2023

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Voxelotor

100 Translational Medicine associated with Voxelotor

100 Patents (Medical) associated with Voxelotor

195

Literatures (Medical) associated with Voxelotor

01 Feb 2026·BLOOD CELLS MOLECULES AND DISEASES

Anti-sickling efficacy and safety of Sailin-HbS, an indigenous Ayurvedic formulation

Article

Author: Dash, Bishnu Prasad ; Gupta, Kalpna ; Bhansali, Anil ; Rajesh, Apratim Sai ; Bhatt, Shruti ; Panda, Pradip Kumar ; Kundu, Suman ; Jena, Rabindra Kumar ; Meher, Satyabrata

Sickle Cell Disease (SCD) is a hereditary condition characterized by a mutation in globin chains of hemoglobin. Polymerization of deoxygenated sickle hemoglobin (HbS) leads to rigid sickle shaped red blood cells (RBC), the primary cause of SCD pathobiology and multiple comorbidities including organ damage and pain. Gene therapy is the only treatment to reduce sickling, but its limitations including high cost, advanced technical resources and age limit pose a major challenge in its application. We examined the potential of a nutraceutical Sailin-HbS, formulated from the extract of 5 different plant sources with anti-oxidant and anti-inflammatory property, to ameliorate RBC sickling. Using sickle RBCs from individuals with SCD (SS-RBCs), Sailin-HbS demonstrated ∼74 % inhibition of sickling under low oxygen conditions; and significantly inhibited hypoxia-induced HbS polymerization by reducing polymerization kinetics at 700 nm. Osmotic fragility tests demonstrated enhanced resistance of SS-RBCs to osmotic stress in the presence of Sailin-HbS. We compared the anti-sickling effect of Sailin-HbS with known anti-sickling agents, Niprisan, SCD 101, AES-103/5-HMF and GBT440/Voxelotor, and found it to be equally and/or more effective. We tested the safety/toxicity of Sailin-HbS in 2 rodent models which showed a high safety threshold, with an oral LD50 exceeding 2000 mg/kg, placing it within the OECD-GHS category class 5. Sub-acute and chronic toxicity assessments in rats reveal no adverse effects on organ function or body weight, biochemical parameters, or complete blood counts, demonstrating its safety profile with established threshold levels. Thus, Sailin-HbS exhibits considerable anti-sickling efficacy without inducing toxicity, suggesting its translational potential in SCD.

01 Oct 2025·ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice

Article

Author: Nicolson, Phillip L.R. ; Cleary, Simon J. ; Watson, Steve P. ; Dimitrov, Jordan D. ; El-Awaisi, Juma ; Rayes, Julie ; Perrella, Gina ; Kavanagh, Dean ; Grygielska, Beata ; Mayor, Nicolas ; Tinkova, Veronika ; Kalia, Neena ; Hassan, Eman ; Brill, Alexander

BACKGROUND::

Sickle cell disease (SCD) is a challenging genetic disorder characterized by hemolytic anemia, vaso-occlusive crises (VOC), and progressive organ damage. Despite its severity, effective treatments are limited. The recent withdrawal of promising therapies, such as the anti–P-selectin antibody Crizanlizumab and the hemoglobin polymerization inhibitor Voxelotor, highlights the urgent need for innovative approaches to alleviate vaso-occlusion and thromboinflammation.

METHODS::

In this study, we used advanced techniques, including intravital microscopy, laser speckle contrast imaging, and histological analysis, to examine the role of syk (spleen tyrosine kinase) in platelet and neutrophil recruitment, and blood perfusion in the lung, kidney, liver, and spleen of SCD mice.

RESULTS::

In the Berkeley SCD model, hemin-induced vaso-occlusion and impairment in pulmonary blood perfusion were independent of red cell congestion and fibrin deposition. Hypoperfusion was driven by adhesion of neutrophils and platelets in the microcirculation and exacerbated by pulmonary emboli. Hemin-induced cell adhesion and hypoperfusion were also observed in the renal microcirculation, whereas it was limited in the liver and spleen of SCD mice, suggesting that organ-specific mechanisms drive hypoperfusion and vaso-occlusion. To explore therapeutic options, we investigated the potential of Syk inhibition in improving blood perfusion and reducing thrombo-inflammation in different organs. Selective Syk inhibition, using BI-1002494, reduced cellular adhesion in the pulmonary and renal microvasculature, effectively restoring blood perfusion and reducing thrombo-inflammation. Low-dose Syk inhibitor was effective in reducing neutrophil adhesion and improving blood perfusion without inducing bleeding. Increasing the dose exacerbated hemin-induced bleeding in the lungs, likely due to off-target activity againt other kinases, including Src.

CONCLUSIONS::

These findings underscore the critical role of Syk in platelet and neutrophil mediated-thrombo-inflammation and hypoperfusion in SCD, suggesting that Syk inhibition is a promising strategy to reduce organ-specific vaso-occlusion, improve renal and pulmonary perfusion, and reduce organ damage.

01 Oct 2025·INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH

A contemporary review of the management strategies for sickle cell disease related ischaemic and stuttering priapism

Review

Author: Kesse-Adu, Rachel ; Shabbir, Majed ; Emmanuel, Anthony ; Moussa, Ahmed

Abstract:

Sickle cell disease is one of the most common autosomal recessive genetic disorders with 23% and over 70% of men with this condition, experiencing episodes of ischaemic priapism and stuttering priapism, respectively, with potentially severe consequences. The effective prevention of sickle cell disease induced ischaemic priapism and stuttering priapism requires a multidisciplinary and multimodal approach. A search of the English literature was performed utilising Pubmed® and Google Scholar to identify publications on contemporary and novel treatment options, with their associated treatment outcomes if available, that are utilised to prevent stuttering priapism episodes and hence a fulminant ischaemic priapism. This narrative review focuses on three main aspects which include firstly, patient education and lifestyle modifications. Secondly, strategies aimed at preventing stuttering priapism episodes with traditional treatments such as alpha-adrenergic agonists and hormone manipulation strategies among others. Finally, we review treatments utilised to treat the underlying sickle cell disease with contemporary options such as hydroxyurea to more novel therapies such as crizanlizumab and voxelotor. The role of potentially curative techniques such as gene therapy and stem cell transplantation are also reviewed and summarised.

176

News (Medical) associated with Voxelotor

19 Nov 2025

·www.fiercepharma.com

Agios readies FDA push in sickle cell disease despite mixed ph. 3 results, shares plummet

Agios' Pyrukynd missed one of its two primary endpoints in a phase 3 sickle cell disease trial, but the company is still plotting an FDA bid next year. In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle cell disease (SCD).Attempting to capture a “broad assessment” of the potential benefits of the drug across “multiple aspects of the disease,” the company ran the 52-week Rise Up study, with primary endpoints assessing hemoglobin responses and the annualized rate of sickle cell pain crises (SCPCs) compared to placebo. The study further examined five secondary endpoints, including other biomarker responses, patient fatigue and the annualized rate of hospitalizations for SCPCs.Rise Up met one primary endpoint by demonstrating an improved hemoglobin response, Agios said on Wednesday, with 40.6% of patients on the drug meeting hemoglobin response criteria, versus 2.9% on placebo. On the other primary measure, however, Pyrukynd showed a “reduction” in SCPCs but did not ultimately achieve statistical significance.On secondary endpoints, the drug showed certain improved biomarker outcomes but failed to show an average change from baseline on a patient-reported fatigue scoring system. Two other secondary measures couldn't be determined, Agios said.Agios plans to “engage with the FDA to discuss these findings and our goal of bringing this innovative medicine to patients with sickle cell disease,” Sarah Gheuens, M.D., Ph.D., chief medical officer, said in the company’s release.“The RISE UP Phase 3 results further support mitapivat’s strong anti-hemolytic profile, as demonstrated in other rare blood disease trials,” Gheuens said. “These effects can help address debilitating features of sickle cell disease that can profoundly worsen quality of life and lead to early mortality.”The company aims to submit its bid for Pyrukynd in SCD after a meeting with the FDA in the first quarter of 2026, the company said.It's tough to get a sense of the drug's outlook in SCD in the wake of the readout, but investors aren't thrilled. The company’s stock price crashed by more than 49% on Wednesday morning, reaching $22.91 by midday, down from its previous close of $45.49.For another indication of how the company is digesting the news, Agios said it's planning to take "proactive steps to reduce operating expenses" to support its financial position and support another potential launch. Pyrukynd won approval in 2022 as the first therapy indicated for hemolytic anemia in adults with PK deficiency. The company’s ambitions to grow beyond its existing patient population have so far faced ups and downs, with last year’s study of Pyrukynd in children with PK deficiency who receive regular transfusions missing its prespecified statistical criterion.Meanwhile, an FDA approval decision in another potential area of expansion, thalassemia, is expected next month after the agency extended its review by three months.Troubles in SCD trialsSickle cell disease challenges aren’t unique to Agios. Besides the 2023 FDA approvals of multimillion-dollar genetic medicines from Genetix Biotherapeutics (formerly known as bluebird bio), Vertex Pharmaceuticals and CRISPR Therapeutics, the field has seen several setbacks lately.Pfizer, for one, last year cut one of its two phase 3 studies evaluating its sickle cell asset, inclacumab and ultimately reported that the remaining study missed its primary vaso-occlusive crises (VOCs) endpoint in August. That setback came after another major stumble for Pfizer’s SCD portfolio—and the oral SCD treatment market as a whole—with the withdrawal of its oral Oxbryta.Oxbryta formed the centerpiece of Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics in 2022, from which the company also got inclacumab. Upon its accelerated FDA approval in 2019, Oxbryta was touted as the first medicine to target the root cause of sickle cell disease. However, that approval was based on a phase 3 study that, like Agios', used a measure of hemoglobin response as its primary efficacy indicator.Years later, when Pfizer pulled the drug from global markets, it cited “the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk” in SCD patients, pointing to data that suggested an “imbalance in vaso-occlusive crises and fatal events.”A February article published in the journal HemaSphere explored the drug development hurdles in SCD. According to the authors, the Oxbryta situation exemplified that although “laboratory endpoints, such as increased hemoglobin levels, are easier to achieve, it is still important to demonstrate some meaningful clinical benefit, such as reduced episodes of pain or improved quality of life.”

Clinical ResultPhase 3Drug ApprovalAcquisitionAccelerated Approval

19 Nov 2025

·endpoints.news

Agios' sickle cell trial falls short as drug doesn't appear to help patient pain crises

Agios Pharmaceuticals’ drug Pyrukynd hit only one of the two primary endpoints in its pivotal trial in sickle cell disease, the company said Wednesday, a significant setback for the company’s plans to expand use of the treatment. The company said that it would still take the data to regulators, in the hope of adding sickle cell to the pill’s label. Pyrukynd is already approved for the rare disease pyruvate kinase deficiency, but sickle cell is much more prevalent and approval could increase the drug’s sales considerably. Its stock $AGIO crashed by 50% on Wednesday in response to the news. Sickle cell patients have genetic mutations that produce malformed hemoglobin, an oxygen-carrying protein in the blood. That can cause anemia and symptoms including tiredness, weakness and shortness of breath. It also causes the characteristic sickle-like shape of patients’ red blood cells, which can become jammed in blood vessels, leading to crippling attacks known as sickle-cell pain crises. In the Phase 3 RISE UP trial, 40.6% of sickle cell patients had hemoglobin levels increase by at least 1.0 g/dL on average, when measured between six months and one year. Among patients on placebo, only 2.9% hit that mark. The difference was statistically significant. The drug works by activating pyruvate kinase, an enzyme involved in energy production in red blood cells. The other primary endpoint was the rate of sickle-cell pain crises. There, Pyrukynd was less clearly effective. Patients on the drug had an average of 2.62 crises on an annualized basis, compared with 3.05 in the placebo arm. The difference wasn’t statistically significant (p=0.1213) Cantor analysts wrote that Agios had always said the trial would need to hit on the hemoglobin endpoint as well as on pain crises or fatigue. “Based on what we saw today, there’s not a clear ‘plus,'” the analysts wrote. They raised doubts about whether the FDA would approve expanded use of Pyrukynd based on hemoglobin alone. The drug also failed to show a benefit on a secondary endpoint measuring fatigue. Other secondary endpoints, looking at hemoglobin concentration and levels of indirect bilirubin, a marker of blood cell destruction known as hemolysis, were met. On Wednesday, Agios touted post-hoc analyses showing that the patients in the Pyrukynd arm who had hemoglobin response also had “clinically meaningful” benefits over placebo in the annualized rates of pain crises and associated hospitalizations, as well as improvements in fatigue. “A 41% response rate is substantial, and given that it has been shown to be a safe drug, that it’s worth giving it a try, to try to improve the patient’s hemoglobin,” said Biree Andemariam, professor of medicine at the University of Connecticut, during the company’s call. Andemariam worked on the trial for the company. But those findings are unlikely to cut much ice with regulators, however, given that less than half of patients in the trial had a hemoglobin response. The drug’s safety profile appeared fairly benign. Serious treatment-emergent adverse events occurred in 20 and 29 patients on Pyrukynd and placebo, respectively. Around 4% of patients on Pyrukynd and 3% on placebo dropped out of the trial because of those adverse effects. Serious side effects determined to be related to treatment were seen in less than 1% of patients on Pyrukynd. Agios said it would submit its request to the FDA in the first quarter of 2026. Chief medical officer Sarah Gheuens said on the conference call that the company saw “a very compelling commercial opportunity,” driven by the unmet need in sickle cell. Pyrukynd is due a US approval decision in its second indication, the genetic blood disorder beta thalassemia, by Dec. 7. The FDA delayed the verdict from Sept. 7 to allow it to assess Agios’ proposed patient safety program, which was necessitated by a liver damage signal that had emerged in clinical trials in thalassemia. No liver toxicity was seen in RISE UP. Last year, Pfizer was forced to pull its sickle cell drug Oxbryta from market, also due to safety concerns. Novo Nordisk is also working on a pyruvate kinase activator, with Phase 3 data due next year. The Danish company hopes to see a 50% reduction in vaso-occlusive crises, which are similar, though differently defined, events to SCPCs.

Phase 3Clinical ResultDrug Approval

19 Nov 2025

·www.biopharmadive.com

Agios shares fall on mixed sickle cell results for blood disease drug

Dive Brief:Agios Pharmaceuticals anemia pill Pyrukynd missed one of two main goals in a Phase 3 trial in sickle cell disease, failing to significantly reduce the number of pain crises that occur from blood vessel blockages when compared to a placebo, the company said Wednesday.The drug, known scientifically as mitapivat, did help people who took it produce more healthy hemoglobin, meeting the studys other main goal, according to Agios. Trial enrollees who had a hemoglobin response were also more likely to see a significant reduction in pain crises. The company intends to discuss an approval application with U.S. regulators, too.Still, Agios share price was nearly halved Wednesday morning, falling from about $45 to $24 apiece. The company has been awaiting a Food and Drug Administration approval in a different type of blood disease, but the agency delayed its decision in September. A verdict is now expected by Dec. 7.Dive Insight:The treatment landscape for sickle cell disease has been something of a roller coaster ride over the last few years. In 2019, a long-used medication, hydroxyurea, was joined by Novartis Adakveo and Pfizers Oxbryta. Genetic medicines from Vertex Pharmaceuticals and Bluebird Bio arrived a few years later. But European regulators have since revoked Adakveos marketing authorization, and Pfizer which spent more than $5 billion to gain control of Oxbryta withdrew the drug in 2024.Uptake for the genetic medicines has been slow, too. Vertex recently reported a total of 165 people have had their first cell collections for its treatment, Casgevy, as of Sept. 30. Before Bluebird was taken private, it recorded $11 million in 2024 sales for a treatment priced at $3.1 million.Those setbacks have left an opportunity for newer entrants such as mitapivat. Sold as Pyrukynd for a rare form of anemia, mitapivat stimulates an enzyme called pyruvate kinase that can aid in red blood cell survival, making it potentially useful in diseases like sickle cell and beta thalassemia. Clearances there could be a boost for Agios, as the drug only generated about $22 million in sales over the first nine months of the year.Agios could still gain one approval in beta thalassemia within the next month. But clearance in sickle cell will hinge on regulators view of the study results disclosed Wednesday.In the trial, titled Rise Up, Agios enrolled 207 people with sickle cell and randomized two-thirds to receive Pyrukynd, with the rest getting a placebo.On the main measure it met, hemoglobin response, Pyrukynd helped 41% of those treated achieve at least a 1 gram per deciliter of blood increase in the oxygen-carrying protein, versus only 3% in the placebo arm. According to Agios, the responders had a mean change in hemoglobin of about 1.6 grams per deciliter.The difference between groups in the annualized rate of sickle cell pain crises, however, didnt reach statistical significance. Those who got Pyrukynd had about 2.6 of these crises per year, versus 3.1 for those who got a placebo.The data from Rise Up demonstrate that treatment with mitapivat significantly improved hemoglobin concentration and reduced hemolysis, said trial investigator Biree Andemariam, a medical professor at University of Connecticut Health, in a statement provided by Agios. We also see that patients who achieved the threshold of hemoglobin response also experienced clinically meaningful benefits in the rate of sickle cell pain crises and hospital visits for those events, as well as in fatigue.If the FDA chooses to review an application for mitapivat in sickle cell disease, it may need to balance that mixed data with an emerging safety concern. The agency is taking extra time to evaluate the drug in beta thalassemia to assess a protocol designed to lower the risk of liver cell damage or inflammation seen in testing against that disease.In announcing the sickle cell results, Agios said liver abnormalities seen in study volunteers were not suggestive of drug-induced hepatocellular injury. '

Clinical ResultPhase 3Drug Approval

100 Deals associated with Voxelotor

External Link

KEGG	Wiki	ATC	Drug Bank
D11330	Voxelotor	B03XA	DB14975

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Hemolytic	European Union	Pfizer Europe MA EEIG	14 Feb 2022
Anemia, Hemolytic	Iceland	Pfizer Europe MA EEIG	14 Feb 2022
Anemia, Hemolytic	Liechtenstein	Pfizer Europe MA EEIG	14 Feb 2022
Anemia, Hemolytic	Norway	Pfizer Europe MA EEIG	14 Feb 2022
Anemia, Sickle Cell	United States	Global Blood Therapeutics, Inc.	25 Nov 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemoglobin SC Disease	Phase 2	United States	Pfizer Inc.	23 Oct 2023
Hemolysis	Phase 2	France	Pfizer Inc.	22 Mar 2023
Chronic Kidney Diseases	Phase 2	United States	Global Blood Therapeutics, Inc.	16 Mar 2021
Semicircular Canal Dehiscence	Phase 2	United Kingdom	Pfizer Inc.	09 Jan 2020
Hypoxia	Phase 2	United States	Global Blood Therapeutics, Inc.	01 Jun 2016
Idiopathic Pulmonary Fibrosis	Phase 2	United States	Global Blood Therapeutics, Inc.	01 Jun 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03573882 (034OLE, CTgov)	Phase 3	Anemia, Sickle Cell	179	Placebo+GBT440 (Prior Treatment of Placebo in GBT440-031 (NCT03036813))	uhscnyfjvh = avbtfaskeh ypbwauvvpa (hbdbehewlz, kthcvmmmhw - mjnjhrvkzk) View more	-	18 Nov 2025
				GBT440 (Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813))	uhscnyfjvh = tlaexkzrzv ypbwauvvpa (hbdbehewlz, ttzmbjscpk - dummmbewfy) View more
NCT04188509 (CTgov)	Phase 3	Anemia, Sickle Cell	162	Voxelotor	xnllkpkhhp = qtyvyktwoi muhdgdgpez (kxqzuyxnrh, rbkewfqeip - abzuzmjugd) View more	-	13 Nov 2025
NCT02850406 (HOPE Kids \| HOPE-KIDS, CTgov)	Phase 2	Anemia, Sickle Cell	147	voxelotor (Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg)	eqbehgkzma(ologgjbett) = cboobsbfpp ybxgjfalse (dydnvnnpxb, 36.39) View more	-	15 Aug 2025
				voxelotor (Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg)	eqbehgkzma(ologgjbett) = vlqdczzqcq ybxgjfalse (dydnvnnpxb, 43.62) View more
NCT05561140 (RESOLVE, CTgov)	Phase 3	Anemia, Sickle Cell	88	voxelotor (Voxelotor (Blinded) + SOC Then Voxelotor (Open Label) + SOC)	wqjvqxyxrz = lryqbnkzlb djjuhxffff (kqfckldqxw, enhgdgdlkb - kxfckyiwbj) View more	-	09 Jul 2025
				Placebo (Placebo (Blinded) + SOC Then Voxelotor (Open Label) + SOC)	wqjvqxyxrz = rrwtnnmqst djjuhxffff (kqfckldqxw, tirasavlxg - rlaabidayx) View more
NCT04218084 (HOPE Kids 2 \| HOPE-KIDS 2, CTgov)	Phase 3	Anemia, Sickle Cell	236	Voxelotor (Voxelotor)	fdmmrbiuvy(hbmhjofkgr) = xrvqfywgjf ffemraemfd (ufdjvdegll, tfnixtxaxr - hvngpnefmn) View more	-	13 Jun 2025
				Placebo (Placebo)	fdmmrbiuvy(hbmhjofkgr) = neftfgvstm ffemraemfd (ufdjvdegll, sqbkjtvifq - mfachpaehq) View more
NCT05199766 (HEMOPROVE, EHA2025)	Phase 2	Anemia, Sickle Cell	13	Voxelotor 1500mg per day	wzbykeelbe(dngoqxgvcy) = qgzodthfkw dgwtncbzme (ptnjfybxhd ) View more	Positive	14 May 2025
				Placebo	wzbykeelbe(dngoqxgvcy) = vphhzjsouo dgwtncbzme (ptnjfybxhd ) View more
ASH2024	Not Applicable	Anemia, Sickle Cell	-	Voxelotor 1500 mg	wzbcrdogbr(swnpfioxbg) = bllsobrxhm zlwuqhmudz (zpyogfuzrn, 6.6 - 7.9) View more	-	08 Dec 2024
ASH2024 \| EURETINA2024	Not Applicable	Anemia, Sickle Cell	-	Voxelotor 1500 mg	yizbezstjn(pnafanosbw) = vjnwgbwvnn ewmgjkvhvz (ruzhalazkc, [1.2 - 7.3]) View more	-	08 Dec 2024
ASH2024	Not Applicable	-	-	Voxelotor 1500 mg daily	yxuhxqlnid(repbxdylzt) = jgchugiewu uyjffhncgq (pagnkwpkzu ) View more	-	08 Dec 2024
				Hydroxyurea (HU)	yxuhxqlnid(repbxdylzt) = zanfglqbcc uyjffhncgq (pagnkwpkzu ) View more
NCT05289570 (Voxelotor, CTgov)	Phase 2	Acute Lung Injury	3	Voxelotor	kxshdeeyly(mhfelmmdjv) = nplxfgaowm dqerjwfzpe (odtqptdvmt, 0.215) View more	-	24 Jul 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis